Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00527423 | Randomized, Single-Masked, Long-Term, Safety and Tolerability Study of VEGF Trap-Eye in AMD | PHASE2 | COMPLETED | 157 | — | — | Aug 1, 2007 | Oct 1, 2011 | Jun 12, 2013 | 33 | United States |
Number of participants with AEs summarized by category
| Arm | Type | Description |
|---|---|---|
| Intravitreal Aflibercept Injection (EYLEA, VEGF Trap-Eye) | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| VEGF Trap Eye | DRUG | Intravitreal injection |
Inclusion Criteria: * Prior participation in VEGF Trap-Eye Phase I and II studies Exclusion Criteria: * Any ocular or systemic adverse events that would preclude participation * Presence of any condition that would jeopardize subject's participation